睿智医药
(300149)
| 流通市值：45.61亿 | | | 总市值：47.82亿 |
| 流通股本：4.82亿 | | | 总股本：5.05亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 562,462,124.29 | 266,689,812.56 | 1,134,719,476.3 | 816,848,135.12 |
| 营业总成本 | 594,175,594.63 | 289,479,241.79 | 1,116,539,022.01 | 815,922,997.79 |
| 其他经营收益 | | | | |
| 营业利润 | -31,626,245.77 | -23,316,598.46 | 23,087,141.68 | 13,928,933.12 |
| 利润总额 | -32,501,244.91 | -23,438,903.76 | 16,012,032.78 | 14,749,487.4 |
| 净利润 | -30,424,418.22 | -18,027,945.95 | 13,553,054.33 | 7,162,056.65 |
| 每股收益 | | | | |
| 其他综合收益 | -8,162,985.04 | -9,785,903.53 | -5,336,908.18 | -2,279,583.73 |
| 综合收益总额 | -38,587,403.26 | -27,813,849.48 | 8,216,146.15 | 4,882,472.92 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 756,316,193.8 | 788,863,348.75 | 765,017,393.1 | 697,464,429.81 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,231,544,286.15 | 1,251,177,709.19 | 1,267,927,806.11 | 1,291,989,135.87 |
| 资产总计 | 1,987,860,479.95 | 2,040,041,057.94 | 2,032,945,199.21 | 1,989,453,565.68 |
| 流动负债: | | | | |
| 流动负债合计 | 346,318,326.63 | 369,610,581.48 | 355,445,229.86 | 332,734,971.55 |
| 非流动负债: | | | | |
| 非流动负债合计 | 335,862,464.65 | 358,984,006.96 | 377,140,438.62 | 378,889,306.57 |
| 负债合计 | 682,180,791.28 | 728,594,588.44 | 732,585,668.48 | 711,624,278.12 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,275,694,466.89 | 1,282,151,610.68 | 1,276,017,116.03 | 1,253,557,011.18 |
| 股东权益合计 | 1,305,679,688.67 | 1,311,446,469.5 | 1,300,359,530.73 | 1,277,829,287.56 |
| 负债和股东权益合计 | 1,987,860,479.95 | 2,040,041,057.94 | 2,032,945,199.21 | 1,989,453,565.68 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 568,647,448.63 | 283,274,396.55 | 1,161,337,279.24 | 865,049,401.47 |
| 经营活动现金流出小计 | 528,678,518.83 | 241,993,532.27 | 970,838,470.92 | 744,814,231.35 |
| 经营活动产生的现金流量净额 | 39,968,929.8 | 41,280,864.28 | 190,498,808.32 | 120,235,170.12 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 51,032,453.55 | 17,715,187.23 | 127,194,956.34 | 79,401,101.08 |
| 投资活动现金流出小计 | 60,286,632.02 | 29,666,177.81 | 197,099,661.45 | 133,887,076.12 |
| 投资活动产生的现金流量净额 | -9,254,178.47 | -11,950,990.58 | -69,904,705.11 | -54,485,975.04 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 45,173,921.57 | 4,923,921.57 | 87,300,000 | 40,300,000 |
| 筹资活动现金流出小计 | 75,990,138.3 | 6,484,746.39 | 167,011,241.28 | 105,352,877.97 |
| 筹资活动产生的现金流量净额 | -30,816,216.73 | -1,560,824.82 | -79,711,241.28 | -65,052,877.97 |
| 汇率变动对现金及现金等价物的影响 | -15,276,838.45 | -8,049,152.71 | 1,149,651.1 | -1,754,786.44 |
| 现金及现金等价物净增加额 | -15,378,303.85 | 19,719,896.17 | 42,032,513.03 | -1,058,469.33 |
| 期末现金及现金等价物余额 | 390,103,080.98 | 425,201,281 | 405,481,384.83 | 362,390,402.47 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -15,378,303.85 | - | 42,032,513.03 | - |